Modeling COVID-19 vaccination strategies in LMICs considering uncertainty in viral evolution and immunity (preprint)

Vaccines against the SARS-CoV-2 virus were developed in record time, but their distribution has been highly unequal. With demand saturating in high-income countries, many low- and middle-income countries (LMIC) finally have an opportunity to acquire COVID-19 vaccines. But the pandemic has taken its toll, and a majority of LMIC populations have partial immunity to COVID-19 disease due primarily to viral infection. This existing immunity, combined with resource limitations, raises the question of how LMICs should prioritize COVID-19 vaccines relative to other competing health priorities. We modify an established computational model, Covasim, to address these questions in four diverse country-like settings under a variety of viral evolution, vaccine delivery, and novel immunity scenarios. Under continued Omicron-like viral evolution and mid-level immunity assumptions, results show that COVID-19 vaccines could avert up to 2 deaths per 1,000 doses if administered to high-risk (60+) populations as prime+boost or annual boosting campaigns. Similar immunization efforts reaching healthy children and adults would avert less than 0.1 deaths per 1,000 doses. Together, these modeling results can help to support normative guidelines and programmatic decision making towards objectively maximizing population health.

The changing impact of vaccines in the COVID-19 pandemic (preprint)

The Omicron wave has left a global imprinting of immunity which changes the COVID landscape. In this study, we simulate six hypothetical variants emerging over the next year and evaluate the impact of existing and improved vaccines. We base our study on South Africa's infection- and vaccination-derived immunity. Our findings illustrate that variant-chasing vaccines will only add value above existing vaccines in the setting where a variant emerges if we can shorten the window between variant introduction and vaccine deployment to under three weeks, an impossible time-frame without significant NPI use. This strategy may have global utility, depending on the rate of spread from setting to setting. Broadly neutralizing and durable next-generation vaccines could avert over three-times as many deaths from an immune-evading variant compared to existing vaccines. Our results suggest it is crucial to develop next-generation vaccines and redress inequities in vaccine distribution to tackle future emerging variants.

Predicting the Unpredictable: How Dynamic COVID-19 Policies and Restrictions Challenge Model Forecasts (preprint)

Between June and August 2020, an agent-based model was used to project rates of COVID-19 infection incidence and cases diagnosed as positive from 15 September to 31 October 2020 for 72 geographic settings. Five scenarios were modelled: a baseline scenario where no future changes were made to existing restrictions, and four scenarios representing small or moderate changes in restrictions at two intervals. Post hoc, upper and lower bounds for number of diagnosed Covid-19 cases were compared with actual data collected during the prediction window. A regression analysis with 17 covariates was performed to determine correlates of accurate projections. It was found that the actual data fell within the lower and upper bounds in 27 settings and out of bounds in 45 settings. The only statistically significant predictor of actual data within the predicted bounds was correct assumptions about future policy changes (OR = 15.04; 95%CI 2.20-208.70; p = 0.016). Frequent changes in restrictions implemented by governments, which the modelling team was not always able to predict, in part explains why the majority of model projections were inaccurate compared with actual outcomes and supports revision of projections when policies are changed as well as the importance of modelling teams collaborating with policy experts.

Predicting the unpredictable: how dynamic COVID-19 policies and restrictions challenge model forecasts (preprint)

IntroductionTo retrospectively assess the accuracy of a mathematical modelling study that projected the rate of COVID-19 diagnoses for 72 locations worldwide in 2021, and to identify predictors of model accuracy. MethodsBetween June and August 2020, an agent-based model was used to project rates of COVID-19 infection incidence and cases diagnosed as positive from 15 September to 31 October 2020 for 72 geographic settings. Five scenarios were modelled: a baseline scenario where no future changes were made to existing restrictions, and four scenarios representing small or moderate changes in restrictions at two intervals. Post hoc, upper and lower bounds for number of diagnosed Covid-19 cases were compared with actual data collected during the prediction window. A regression analysis with 17 covariates was performed to determine correlates of accurate projections. ResultsThe actual data fell within the lower and upper bounds in 27 settings and out of bounds in 45 settings. The only statistically significant predictor of actual data within the predicted bounds was correct assumptions about future policy changes (OR = 15.04; 95%CI 2.20-208.70; p=0.016). ConclusionsFor this study, the accuracy of COVID-19 model projections was dependent on whether assumptions about future policies are correct. Frequent changes in restrictions implemented by governments, which the modelling team was not always able to predict, in part explains why the majority of model projections were inaccurate compared with actual outcomes and supports revision of projections when policies are changed as well as the importance of policy experts collaborating on modelling projects.

Susceptibility of zero community transmission regimes to new variants of SARS-CoV-2: a modelling study of Queensland (preprint)

Objectives: To assess the risk of sustained community transmission of SARS-CoV-2/COVID-19 in Queensland (Australia) in the presence of high-transmission variants of the virus. Design: We used an agent-based model Covasim and the demographics, policies, and interventions implemented in the state. Using the calibrated model, we simulated possible epidemic trajectories that could eventuate due to leakage of infected cases with high-transmission variants, during a period of zero community transmission. Setting: Model calibration covered the first-wave period from early March 2020 to May 2020. Predicted epidemic trajectories were simulated from early February 2021 to late March 2021. Participants: None (simulation study). Main outcomes: A calibrated model of COVID-19 epidemiology in Queensland; the conditions that could lead to an outbreak; and how likely that situation is to occur. Results: Simulations showed that one infected agent with the ancestral (A.2.2) variant has a 14% chance of crossing a threshold of sustained community transmission (i.e., > 5 infections per day, more than 3 days in a row), assuming no change in the prevailing preventative and counteracting policies. However, one agent carrying a more infectious variant (e.g., B.1.1.7) has a 43% chance of crossing the same threshold; a threefold increase. Doubling the average number of daily tests results in a decrease of this probability from 43% to 23%. Conclusions: The introduction of even a small number of people infected with high-transmission variants dramatically increases the probability of sustained community transmission in Queensland.

COVID-19 reopening strategies at the county level in the face of uncertainty: Multiple Models for Outbreak Decision Support (preprint)

Policymakers make decisions about COVID-19 management in the face of considerable uncertainty. We convened multiple modeling teams to evaluate reopening strategies for a mid-sized county in the United States, in a novel process designed to fully express scientific uncertainty while reducing linguistic uncertainty and cognitive biases. For the scenarios considered, the consensus from 17 distinct models was that a second outbreak will occur within 6 months of reopening, unless schools and non-essential workplaces remain closed. Up to half the population could be infected with full workplace reopening; non-essential business closures reduced median cumulative infections by 82%. Intermediate reopening interventions identified no win-win situations; there was a trade-off between public health outcomes and duration of workplace closures. Aggregate results captured twice the uncertainty of individual models, providing a more complete expression of risk for decision-making purposes.

The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN (preprint)

The widespread occurrence of SARS-CoV-2 has had a profound effect on society and a vaccine is currently being developed. Angiotensin-converting enzyme 2 (ACE2) is the primary host cell receptor that interacts with the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Although pneumonia is the main symptom in severe cases of SARS-CoV-2 infection, the expression levels of ACE2 in the lung is low, suggesting the presence of another receptor for the spike protein. In order to identify the additional receptors for the spike protein, we screened a receptor for the SARS-CoV-2 spike protein from the lung cDNA library. We cloned L-SIGN as a specific receptor for the N-terminal domain (NTD) of the SARS-CoV-2 spike protein. The RBD of the spike protein did not bind to L-SIGN. In addition, not only L-SIGN but also DC-SIGN, a closely related C-type lectin receptor to L-SIGN, bound to the NTD of the SARS-CoV-2 spike protein. Importantly, cells expressing L-SIGN and DC-SIGN were both infected by SARS-CoV-2. Furthermore, L-SIGN and DC-SIGN induced membrane fusion by associating with the SARS-CoV-2 spike protein. Serum antibodies from infected patients and a patient-derived monoclonal antibody against NTD inhibited SARS-CoV-2 infection of L-SIGN or DC-SIGN expressing cells. Our results highlight the important role of NTD in SARS-CoV-2 dissemination through L-SIGN and DC-SIGN and the significance of having anti-NTD neutralizing antibodies in antibody-based therapeutics.

Comparison of SARS-CoV-2 infection in two non-human primate species: rhesus and cynomolgus macaques (preprint)

SARS-CoV-2 is a coronavirus that sparked the current COVID-19 pandemic. To stop the shattering effect of COVID-19, effective and safe vaccines, and antiviral therapies are urgently needed. To facilitate the preclinical evaluation of intervention approaches, relevant animal models need to be developed and validated. Rhesus macaques (Macaca mulatta) and cynomolgus macaques (Macaca fascicularis) are widely used in biomedical research and serve as models for SARS-CoV-2 infection. However, differences in study design make it difficult to compare and understand potential species-related differences. Here, we directly compared the course of SARS-CoV-2 infection in the two genetically closely-related macaque species. After inoculation with a low passage SARS-CoV-2 isolate, clinical, virological, and immunological characteristics were monitored. Both species showed slightly elevated body temperatures in the first days after exposure while a decrease in physical activity was only observed in the rhesus macaques and not in cynomolgus macaques. The virus was quantified in tracheal, nasal, and anal swabs, and in blood samples by qRT-PCR, and showed high similarity between the two species. Immunoglobulins were detected by various enzyme-linked immunosorbent assays (ELISAs) and showed seroconversion in all animals by day 10 post-infection. The cytokine responses were highly comparable between species and computed tomography (CT) imaging revealed pulmonary lesions in all animals. Consequently, we concluded that both rhesus and cynomolgus macaques represent valid models for evaluation of COVID-19 vaccine and antiviral candidates in a preclinical setting.

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research (preprint)

Motivation: In the event of an outbreak due to an emerging pathogen, time is of the essence to contain or to mitigate the spread of the disease. Drug repositioning is one of the strategies that has the potential to deliver therapeutics relatively quickly. The SARS-CoV-2 pandemic has shown that integrating critical data resources to drive drug-repositioning studies, involving host-host, host-pathogen and drug-target interactions, remains a time-consuming effort that translates to a delay in the development and delivery of a life-saving therapy. Results: Here, we describe a workflow we designed for a semi-automated integration of rapidly emerging datasets that can be generally adopted in a broad network pharmacology research setting. The workflow was used to construct a COVID-19 focused multimodal network that integrates 487 host-pathogen, 74,805 host-host protein and 1,265 drug-target interactions. The resultant Neo4j graph database named "Neo4COVID19" is accessible via a web interface and via API calls based on the Bolt protocol. We believe that our Neo4COVID19 database will be a valuable asset to the research community and will catalyze the discovery of therapeutics to fight COVID-19. Availability: https://neo4covid19.ncats.io . Keywords: SARS-CoV-2, COVID-19, network pharmacology, graph database, Neo4j, data integration, drug repositioning

Robust test and trace strategies can prevent COVID-19 resurgences: a case study from New South Wales, Australia (preprint)

Background: The early stages of the COVID-19 pandemic illustrated that SARS-CoV-2, the virus that causes the disease, has the potential to spread exponentially. Therefore, as long as a substantial proportion of the population remains susceptible to infection, the potential for new epidemic waves persists even in settings with low numbers of active COVID-19 infections, unless sufficient countermeasures are in place. In this study, we examine the Australian state of New South Wales, a setting with prolonged low transmission, high mobility, non-universal mask usage, and a well-functioning test-and-trace system. We investigate how vulnerable the state would be to resurgences in COVID-19 transmission under variations in the levels of testing, tracing, and mask usage. Methods: We use a stochastic agent-based model, calibrated to the New South Wales epidemic and policy environment, to simulate possible epidemic outcomes over October 1 to December 31, 2020, under a range of assumptions about contact tracing efficacy, testing rates, and mask uptake. Results: We find that the relative impact of masks is greatest when testing and tracing rates are lower (and vice versa). With very high testing rates (90% of people with symptoms, plus 90% of people with a known history of contact with a confirmed case), we estimate that the epidemic would remain under control until at least the end of 2020, with as little as 70-110 new infections estimated over October 1 to December 31 under high mask uptake scenarios, or 340-1400 without masks, depending on the efficacy of community contact tracing. However, across comparable levels of mask uptake and contact tracing, the number of infections over this period would be up to 6 times higher if the testing rate was 80% instead of 90%, 17 times higher if the testing rate was 65%, or more than 100 times higher with a 50% testing rate. Conclusions: Our work suggests that testing, tracing and masks can all be effective means of controlling transmission in dynamic community settings. A multifaceted strategy that combines all three, alongside continued hygiene and distancing protocols, is likely to be the most robust means of controlling community-based transmission of SARS-CoV-2.

The potential contribution of face coverings to the control of SARS-CoV-2 transmission in schools and broader society in the UK: a modelling study (preprint)

Recent findings suggest that an adequate test-trace-isolate (TTI) strategy is needed to prevent a secondary COVID-19 wave with the reopening of society in the UK. Here we assess the potential importance of mandatory masks in the parts of community and in secondary schools. We show that, assuming current TTI levels, adoption of masks in secondary schools in addition to community settings can reduce the size of a second wave, but will not prevent it; more testing of symptomatic people, tracing and isolating of their contacts is also needed. To avoid a second wave, with masks mandatory in secondary schools and in certain community settings, under current tracing levels, 68% or 46% of those with symptomatic infection would need to be tested if masks' effective coverage were 15% or 30% respectively, compared to 76% and 57% if masks are mandated in community settings but not secondary schools.

Schools are not islands: Balancing COVID-19 risk and educational benefits using structural and temporal countermeasures (preprint)

Background: School closures around the world contributed to reducing the transmission of COVID-19. In the face of significant uncertainty around the epidemic impact of in-person schooling, policymakers, parents, and teachers are weighing the risks and benefits of returning to in-person education. In this context, we examined the impact of different school reopening scenarios on transmission within and outside of schools and on the share of school days that would need to be spent learning at a distance. Methods: We used an agent-based mathematical model of COVID-19 transmission and interventions to quantify the impact of school reopening on disease transmission and the extent to which school-based interventions could mitigate epidemic spread within and outside schools. We compared seven school reopening strategies that vary the degree of countermeasures within schools to mitigate COVID-19 transmission, including the use of face masks, physical distancing, classroom cohorting, screening, testing, and contact tracing, as well as schedule changes to reduce the number of students in school. We considered three scenarios for the size of the epidemic in the two weeks prior to school reopening: 20, 50, or 110 detected cases per 100,000 individuals and assumed the epidemic was slowly declining with full school closures. For each scenario, we calculated the percentage of schools that would have at least one person arriving at school with an active COVID-19 infection on the first day of school; the percentage of in-person school days that would be lost due to scheduled distance learning, symptomatic screening or quarantine; the cumulative infection rate for students, staff and teachers over the first three months of school; and the effective reproduction number averaged over the first three months of school within the community. Findings: In-person schooling poses significant risks to students, teachers, and staff. On the first day of school, 5-42% of schools would have at least one person arrive at school with active COVID-19, depending on the incidence of COVID in the community and the school type. However, reducing class sizes via A/B school scheduling, combined with an incremental approach that returns elementary schools in person and keeps all other students remote, can mitigate COVID transmission. In the absence of any countermeasures in schools, we expect 6-25% of teaching and non-teaching staff and 4-20% of students to be infected with COVID in the first three months of school, depending upon the case detection rate. Schools can lower this risk to as low as 0.2% for staff and 0.1% for students by returning elementary schools with a hybrid schedule while all other grades continue learning remotely. However, this approach would require 60-85% of all school days to be spent at home. Despite the significant risks to the school population, reopening schools would not significantly increase community-wide transmission, provided sufficient countermeasures are implemented in schools. Interpretation: Without extensive countermeasures, school reopening may lead to an increase in infections and a significant number of re-closures as cases are identified among staff and students. Returning elementary schools only with A/B scheduling is the lowest risk school reopening strategy that includes some in-person learning.

The role of masks in reducing the risk of new waves of COVID-19 in low transmission settings: a modeling study (preprint)

Objectives: To evaluate the risk of a new wave of coronavirus disease 2019 (COVID-19) in a setting with ongoing low transmission, high mobility, and an effective test-and-trace system, under different assumptions about mask uptake. Design: We used a stochastic agent-based microsimulation model to create multiple simulations of possible epidemic trajectories that could eventuate over a five-week period following prolonged low levels of community transmission. Setting: We calibrated the model to the epidemiological and policy environment in New South Wales, Australia, at the end of August 2020. Participants: None Intervention: From September 1, 2020, we ran the stochastic model with the same initial conditions (i.e., those prevailing at August 31, 2020), and analyzed the outputs of the model to determine the probability of exceeding a given number of new diagnoses and active cases within five weeks, under three assumptions about future mask usage: a baseline scenario of 30% uptake, a scenario assuming no mask usage, and a scenario assuming mandatory mask usage with near-universal uptake (95%). Main outcome measure: Probability of exceeding a given number of new diagnoses and active cases within five weeks. Results: The policy environment at the end of August is sufficient to slow the rate of epidemic growth, but may not stop the epidemic from growing: we estimate a 20% chance that NSW will be diagnosing at least 50 new cases per day within five weeks from the date of this analysis. Mandatory mask usage would reduce this to 6-9%. Conclusions: Mandating the use of masks in community settings would significantly reduce the risk of epidemic resurgence.

Controlling COVID-19 via test-trace-quarantine (preprint)

COVID-19 containment efforts in the United States so far have largely focused on physical distancing, including school and workplace closures. However, these interventions have come at an enormous societal and economic cost. Here, we use an agent-based model, calibrated to detailed demographic, mobility, and epidemiological data for the Seattle region, to investigate the feasibility of alternative control strategies, focusing on "test-trace-quarantine": a combination of (a) routine testing of primarily symptomatic individuals, (b) tracing and testing their known contacts, and (c) placing their contacts in quarantine. We assess the requirements for implementing this strategy, including its robustness to low compliance, delays, and other factors such as variability in overall transmission rates. We find that for the Seattle setting, if mask compliance remains high and schools remain closed, realistic levels of testing and tracing are sufficient to maintain epidemic control under a return to full workplace and community mobility.

Modelling the impact of reducing control measures on the COVID-19 pandemic in a low transmission setting (preprint)

Aims: We assessed COVID-19 epidemic risks associated with relaxing a set of physical distancing restrictions in the state of Victoria, Australia - a setting with low community transmission - in line with a national framework that aims to balance sequential policy relaxations with longer-term public health and economic need. Methods: An agent-based model, Covasim, was calibrated to the local COVID-19 epidemiological and policy environment. Contact networks were modelled to capture transmission risks in households, schools and workplaces, and a variety of community spaces (e.g. public transport, parks, bars, cafes/restaurants) and activities (e.g. community or professional sports, large events). Policy changes that could prevent or reduce transmission in specific locations (e.g. opening/closing businesses) were modelled in the context of interventions that included testing, contact tracing (including via a smartphone app), and quarantine. Results: Policy changes leading to the gathering of large, unstructured groups with unknown individuals (e.g. bars opening, increased public transport use) posed the greatest risk, while policy changes leading to smaller, structured gatherings with known individuals (e.g. small social gatherings) posed least risk. In the model, epidemic impact following some policy changes took more than two months to occur. Model outcomes support continuation of working from home policies to reduce public transport use, and risk mitigation strategies in the context of social venues opening, such as >30% population-uptake of a contact-tracing app, physical distancing policies within venues reducing transmissibility by >40%, or patron identification records being kept to enable >60% contact tracing. Conclusions: In a low transmission setting, care should be taken to avoid lifting sequential COVID-19 policy restrictions within short time periods, as it could take more than two months to detect the consequences of any changes. These findings have implications for other settings with low community transmission where governments are beginning to lift restrictions.

Covasim: an agent-based model of COVID-19 dynamics and interventions (preprint)

The COVID-19 pandemic has created an urgent need for models that can project epidemic trends, explore intervention scenarios, and estimate resource needs. Here we describe the methodology of Covasim (COVID-19 Agent-based Simulator), an open-source model developed to help address these questions. Covasim includes demographic information on age structure and population size; realistic transmission networks in different social layers, including households, schools, workplaces, and communities; age-specific disease outcomes; and intrahost viral dynamics, including viral-load-based transmissibility. Covasim also supports an extensive set of interventions, including non-pharmaceutical interventions, such as physical distancing, hygiene measures, and protective equipment; and testing interventions, such as symptomatic and asymptomatic testing, isolation, contact tracing, and quarantine. These interventions can incorporate the effects of delays, loss-to-follow-up, micro-targeting, and other factors. In collaboration with local health agencies and policymakers, Covasim has already been applied to examine disease dynamics and policy options in Africa, Europe, Oceania, and North America.